Carbohydrate anti-tumor drugs are a new type of anti-tumor preparation developed based on carbohydrate compounds, which exert their effects by targeting tumor cell metabolism or regulating the immune system. These drugs typically have natural polysaccharides, oligosaccharides, or synthetic sugar conjugates as their core structures, which can interfere with the energy metabolism of tumor cells, inhibit glycosylation processes, or block glycoprotein mediated cell signaling, thereby inhibiting tumor proliferation and metastasis. Compared to traditional chemotherapy drugs, carbohydrate anti-tumor drugs have higher targeting and lower toxic side effects. For example, heparin derivatives can inhibit tumor angiogenesis, and chitosan complexes can enhance immune cell activity.Anti-tumor glycodrugs leverage their unique sugar chain structures to precisely target tumor cells, enhancing biocompatibility and therapeutic efficacy. The sugar chains bind to specific receptors on tumor cell surfaces, inhibiting proliferation, migration, and angiogenesis while inducing apoptosis. Additionally, glycodrugs modulate the immune microenvironment, activating immune cells (e.g., LAK, NK cells) and boosting the body's anti-tumor immune response. Their low toxicity and high targeting specificity make them promising candidates for cancer treatment.The wide variety of medications has greatly met people's needs.
In the forefront of cancer treatment research, precise and comprehensive data resources play a decisive role in the development of anti-tumor drugs. As a novel anti-cancer tool, nucleic acid-based drugs leverage the unique biological properties of nucleic acid molecules to precisely interfere with critical life processes of cancer cells, such as gene expression and signal transduction, offering new hope for combating cancer. However, the development of such drugs faces numerous challenges, from nucleic acid sequence design and carrier construction to preclinical and clinical studies. Each step requires extensive experimental data and in-depth mechanistic analysis. The Anti-Tumor Nucleic Acid Drug Database is a critical auxiliary tool designed to address these challenges. It extensively compiles research findings on various nucleic acid-based anti-tumor drugs, including a wide range of screened nucleic acid sequences, carrier types, and related compound information. The database provides in-depth analyses of drug targets, such as cancer-specific genes and regulatory proteins, along with detailed evaluations of their activity in multiple cancer cell lines (e.g., MCF-7, PC-3, SK-BR-3). It also explores mechanisms of action, such as how these drugs influence cancer cell proliferation, apoptosis, and metastasis. To date, the database has cataloged information on over 100 nucleic acid-based drugs with potential anti-tumor activityBy utilizing this database, researchers can swiftly access key data to establish a solid theoretical foundation for developing novel anti-tumor nucleic acid drugs, significantly shortening development cycles and reducing costs. This not only accelerates the translation of laboratory discoveries into clinical applications but also holds promise for providing cancer patients with more effective treatment options, improving their quality of life and survival rates, and driving sustained progress in the field of oncology.
In today's stable society, health is the most important thing in people's hearts, and health is closely related to medicine. Accurate and efficient data can help researchers or doctors quickly screen for suitable anti-tumor compounds. It integrates data from medicinal chemistry, pharmacology and pharmacogenomics, and records the chemical structure, targets, and mechanism of action of anti-tumor drugs in detail. The establishment of the database of anti-tumor protein drugs can effectively promote the process development process of innovative drugs and generic drugs. To provide a sharing platform for researchers and clinicians to exchange and share research results and clinical experience of anti-tumor drugs, and to promote academic exchanges and cooperation in the field. It can help doctors quickly obtain the indications and contraindications of drugs, and formulate accurate treatment plans for patients based on their conditions and genetic characteristics. To a certain extent, the database can promote the innovation and development of new drugs, help improve R&D efficiency, reduce procurement and trial costs, and achieve sustainable research.